(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the final Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs rule: “PCMA applauds CMS for delaying the
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), discusses the root cause of high drug prices – big drug companies’ anti-competitive tactics used to keep more affordable prescription drugs from entering
In case you missed it, a new article in Inside Health Policy reported that “Investors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities
This week, the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee considers legislation that would lower choice in the market by creating a one-size-fits all pharmacy benefit contracting model for health plans and employers. As Congress considers mandating contracting
PBMs Reduce Insulin Costs PBMs are working to improve the lives of patients living with diabetes and their families Insulin prices are high because there are only a few insulin manufacturers, shielded from competition, and those companies set and raise
Pharmacy Direct and Indirect Remuneration (DIR) Value-based Pharmacy Reimbursement Reduces Drug Costs for Medicare Beneficiaries, Lowers Spending. Pharmacy direct and indirect remuneration, or Pharmacy DIR, is a form of value-based contracting in Medicare Part D. Pharmacy DIR increases the quality
This week, community pharmacists will conduct a “Fly-In” in Washington D.C. Undoubtedly, part of the message to Congress will be critical of pharmacy benefit companies, but more than likely what won’t be heard is how PBMs are supporting rural pharmacies
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Senate Judiciary Committee hearing, “Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition:” “We applaud the Senate Judiciary Committee
(Washington, D.C.) — A new report, prepared by the research firm Milliman, analyzed the financial impact of broad “Frozen Formulary” legislation in the fully insured commercial market on a nationwide basis. This study found that “Frozen Formulary” legislation could increase nationwide
©2024 PCMA. All Rights Reserved.
